Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae;Izbor antimikrobnog lijeka u liječenju infekcija uzrokovanih bakterijama Chlamydia trachomatis i Chlamydophila pneumoniae

Acta Medica Croatica

Volumn 58, Issue 4, 2004, Pages 329-333

  Žele Starčević, Lidija ^a   Plečko, Vanda ^a   Budmir, Ana ^a   Kalenić, Smilja ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Chlamydia trachomatis; Chlamydophila pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; OFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ATHEROSCLEROSIS; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; HEALTH CENTER; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PREVALENCE; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SEXUALLY TRANSMITTED DISEASE; SINUSITIS; STANDARD; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; BACTERIAL INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 12344289142     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Mahony JB, Coombes BK, Chernesky MA. Chlamydia and Chlamydophila. U: Murray PR, Baron EJ, Jorgensen JH i sur, ur. Manual of Clinical Microbiology. 8. izd. Washington, DC: ASM Press, 2003, 991-1004.
2. Weinstock H, Dean D, Bolan G. Chlamydia trachomatis infections: sexually transmitted diseases in the AIDS era, part II. Infect Dis Clin N Am 1994; 8: 797-819.
3. Aleraj B. Zarazne bolesti u Hrvatskoj 2002. Zagreb: Epidemiološki odjel HZJZ 2003, 25.
4. Topalović Z. Važnost prevencije spolno prenosivih bolesti. Medicus 2003; 12: 253-6.
5. Hiršl-Hečej V. Screening na genitalnu klamidiju u adolescentica i mladih žena u Srednjoj i Istočnoj Europi - Chlamydia Trachomatis Study Group. U: Knjiga sažetaka 6. simpozija o spolno prenosivim bolestima i urogenitalnim infekcijama, Opatija, 2004.
6. Žele-Starčevíc L, Skerlev M, Plečko V, Ljubojević S, Kalenić S. Najčešći bakterijski uzročnici spolno prenosivih bolesti. U: Priručnik stalnog medicinskog usavršavanja »Spolno prenosive bolesti i infekcije«. Zagreb: Medicinska naklada, 2003, 15-18.
7. Škerk V, Schönwald S, Baršić B, Car V, Kružić V. Klamidija trahomatis u urogenitalnim infekcijama. Pharmaca 1999; 37: 75-86.
8. Schachter J, Stoner E, Moncada J. Screening for chlamydial infections in women attending family planning clinics. West J Med 1983; 138: 375-9.
9. Cates W, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequellae. Am J Obstet Gynecol 1991; 164: 1771-81.
10. Oriel JD, Reeve P, Powis P, Miller A, Nicil CS. Chlamydial infection. Isolation of Chlamydia trachomatis from patients with non-specific genital infection. Br J Vener Dis 1972; 48: 429-36.
11. Berger RE, Holmes KK, Mayo ME, Reed R. The clinical use of epididymal aspiration cultures in the management of selected patients with acute epididymitis. J Urol 1980; 124: 60-1.
12. Keat AC. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med 1983; 309: 1606-15.
13. Škerk V, Schönwald S, Krhen I i sur. Aetiology of chronic prostatitis. Int J Antimicrob Agents 2002; 19: 471-4.
14. Rönnerstam P, Persson K, Hansson H i sur. Prevalence of chlamydial eye infection in patients attending an eye clinic, a VD clinic, and in healthy persons. Br J Ophthalmol 1985; 69: 385-88.
15. Persson K, Rönnerstam P, Scanberg L i sur. Neonatal chlamydial eye infection: an epidemiological and clinical study. Br J Ophthalmol 1983; 67: 700-4.
16. Schachter J, Grossman M, Sweet RL i sur. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA 1986; 255: 3374-77.
17. Centers for Disease and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR 2002; 51 (No. RR-1): 33-5.
18. Blythe MJ, Katz BP, Batteiger BE, Ganser JA, Jones RB. Recurrent genitourinary chlamydial infections in sexually active female adolescents. J Pediatr 1992; 121: 487-93.
19. Munday PE, Thomas BJ, Gilroy CB, Gilchrist C, Taylor- Robinson D. Infrequent detection of Chlamydia trachomatis in a longitudinal study of women with treated cervical infection. Genitourin Med 1995; 71: 2A-6.
20. Grayston JT, Wang SP. New knowledge of chlamydiae and the diseases they cause. J Infect Dis 1975; 132: 87-105.
21. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58: 686-99.
22. Gomberg M. Perzistentna klamidijska infekcija. Medicus 2003; 12: 179-88.
23. Meyer KF, Eddie B. Latent psittacosis infection in shell parakeets. Proc Soc Exp Biol Med 1933; 30: 483-8.
24. Mourad A, Sweet RL, Sugg N, Schachter J. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob Agents Chemother 1980; 18: 696-8.
25. Jones RB, Van Der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990; 162: 1309-15.
26. Chambers HF. Methicillin-resistant staphylococci Clin Microbiol Rev 1988; 1: 173-86.
27. Hackbarth CJ, Chambers HF. Methiciuin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother 1989; 33: 991-4.
28. Lefevre JC, Lepargneur JP. Comparative in vitro susceptibility of tetracydine-resistant Chlamydia trachomatis isolated in Toulouse (France). Sex Transm Dis 1998; 25: 350-2.
29. Somani J, Bhullar VB, Workowski KA, Farshy GE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181: 1421-7.
30. Dean D, Suchland RJ, Stamm WE. Apparent long term persistence of Chlamydia trachomatis cervical infections: analysis of OMP 1 genotyping. U: Stephen RS, Byrne GI, Christiansen G i sur, ur. Chlamydial infections. San Francisco: International Chlamydia Symposium, 1998, 31-4.
31. Cotter TW, Miranpuri GS, Ramsey KH, Poulsen CE, Byrne GI. Reactivation of chlamydial genital infection in mice. Infect Immun 1997; 65: 2067-73.
32. Cunningham DS. Immune response characteristics in women with chlamydial genital tract infection. Gynecol Obstet Invest 1995; 90: 3998-4002.
33. Jones RB, Katz BP, Van Der Pol B i sur. Effect of blind passage and multiple sampling on recovery of Chlamydia trachomatis from urogenital specimens. J Clin Microbiol 1986; 24: 1029-33.
34. Bowden FJ, Savage J. Donovasiosis: treatment with azithromycin. (comment). Int J STD AIDS 1998; 9: 61-2.
35. Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous - infection model. Antimicrob Agents Chemother 2002; 46: 409-12.
36. Grayston JT, Campbell LA, Kuo CC i sur. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-25.
37. Grayston JT, Aldous MB, Easton A i sur. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 1993; 168: 1231-5.
38. Block SL, Hammerschlag MR, Hedrick J i sur. Chlamydia pneumoniae in acute otitis media. Pediatr Infect Dis J 1997; 16: 858-62.
39. Weiss SM, Hammerschlag MR. Are heart attacks infectious? A critical look at the link between Chlamydia pneumoniae and atherosclerosis. Bull Inst Pasteur 1997; 95: 107-13.
40. Hammerschlag MR. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J Antimicrob Chemother 2000; 45 (Suppl. S1): 35-9.
41. Barry AI, Fuchs PC. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J Chemother 1997; 9: 9-16.
42. Maskell JP, Whiley AC, Sefton AM. In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis. Eur J Clin Microbiol Infect Dis 1998; 17: 293-5.
43. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51Suppl 1: 1-11.
44. Wise R. Maximizing efficasy and reducing the emergence of resistance. J Antimicrob Chemother 2003; 51Suppl 1: 37-42.
45. Block S, Hedrick J, Hammerschlag MR, Cassel GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficasy and safety of clarithromytin vs erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14: 471-7.
46. Hammerschlag MR, Roblin PM. Microbiological efficasy of moxifloxacin for the treatment of community - acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000; 15: 149-52.
47. Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficasy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J 1998; 17: 865-71.
48. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community- acquired pneumonia. Antimicrob Agents Chemother 1998; 42: 194-6.